Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2021 | HDACIs in treating r/r PTCL

Won-Seog Kim • 21 Jun 2021
ICML 2021
Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases HBI-8000

Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, summarizes the results of the Phase IIb trial (NCT02953652) assessing HBI-8000, a histone deacetylase inhibitor (HDACI), in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 55 patients were enrolled with a durable response rate reported. Patients with angioimmunoblastic T-cell lymphoma (AITL) additionally had a higher response rate, suggesting an increased role of HDACIs and demethylating agents in treating ATIL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals